Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma
确定 SETD2 失活对肺腺癌的影响
基本信息
- 批准号:10539347
- 负责人:
- 金额:$ 43.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-10 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:AllelesAutomobile DrivingBiogenesisBiological ModelsBuffersCRISPR/Cas technologyCarbonCell ProliferationCell RespirationCell divisionCellsChromatinClinicalConsumptionDataDefectDevelopmentDietary intakeDiseaseDrug TargetingEnzymesFrequenciesGene ExpressionGenesGenetic TranscriptionGlobal ChangeGoalsGrowthHistone H3HistonesHumanHuman Cell LineHypoxia Inducible FactorIn VitroIsotope LabelingKRAS2 geneKRASG12DLinkLipidsLoxP-flanked alleleLung AdenocarcinomaLysineMalignant NeoplasmsMalignant neoplasm of lungMetabolicMetabolic PathwayMetabolismMethionineMethylationMethyltransferaseMitochondriaMolecularMolecular AbnormalityMusMutateMutationOncogenicOxidative PhosphorylationPPAR gammaPathway interactionsPatientsPharmaceutical PreparationsPhenotypePost-Translational Protein ProcessingProtein BiosynthesisProteomicsPublishingRegulationRegulator GenesS-AdenosylhomocysteineS-AdenosylmethionineSerineSignal TransductionSupporting CellSystemTestingTherapeuticTumor PromotionTumor Suppressor ProteinsWorkcancer cellcancer typecell growthclinical efficacydietarydietary restrictionefficacy evaluationenzyme mechanismhistone methyltransferasein vivoinhibitorlipidomicsloss of functionmetabolomicsmouse modelneoplastic cellnovel therapeutic interventionpatient derived xenograft modelpre-clinicalprogramsrational designsynthetic lethal interactiontranscription factortumortumor progression
项目摘要
PROJECT SUMMARY
SETD2 is mutationally inactivated in many cancer types including lung adenocarcinoma. In published
work, we demonstrated that Setd2 inactivation has potent tumor promoting effects in an autochthonous mouse
model of KRASG12D-driven lung adenocarcinoma. SETD2 uniquely catalyzes histone H3 lysine 36
trimethylation (H3K36me3), which marks actively transcribed gene bodies, facilitating chromatin resetting after
gene transcription. In the current project, we aim to understand the provocative observation that SETD2
inactivation potently drives tumor cell proliferation due to a defect in one-carbon metabolism and activation of
mTORC1 signaling. We demonstrate that SETD2 loss is associated with an enrichment in the abundance of S-
adenosyl methionine (SAM) and multiple other metabolites that are part of SAM-adjacent metabolic pathways.
We will test the hypothesis that the disuse of SAM that results from the lost activity of the SETD2
methyltransferase leads to SAM accumulation, enhanced one-carbon metabolism, and activation of mTORC1
signaling, all supporting cell growth and proliferation. Consistent with this hypothesis, we demonstrate that
limiting dietary intake of methionine reduces KRAS-driven lung adenocarcinoma growth and reverses the
effects of SETD2 inactivation. Thus, we will assess the efficacy of clinical and pre-clinical drugs that target the
methionine cycle for potential synthetic lethal interactions with SETD2 deficiency. Finally, downstream of
activated mTORC1 signaling we observe prominent transcriptional programs of hypoxia inducible factors
(HIFs) and peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1 α (PGC1α). Consistently, we
observe multiple pathophysiological changes that are associated with increased activation of HIF and PGC1α
transcription, such as alterations in mitochondrial biogenesis and the co-enhancement of oxidative
phosphorylation and glycolytic pathways. Thus, we will test the requirement of these master transcription
factors for effectuating phenotypes downstream of SETD2 inactivation.
项目概要
SETD2 在包括肺腺癌在内的许多癌症类型中发生突变失活。
工作中,我们证明 Setd2 失活对本地小鼠具有有效的肿瘤促进作用
KRASG12D 驱动的肺腺癌模型 SETD2 独特地催化组蛋白 H3 赖氨酸 36。
三甲基化(H3K36me3),标记活跃转录的基因体,促进染色质在转录后重置
在当前的项目中,我们的目标是了解 SETD2 的令人兴奋的观察结果。
由于一碳代谢和激活的缺陷,失活可有效驱动肿瘤细胞增殖
我们证明 SETD2 丢失与 S- 丰度的富集有关。
腺苷甲硫氨酸 (SAM) 和属于 SAM 邻近代谢途径一部分的多种其他代谢物。
我们将测试以下假设:由于 SETD2 活性丧失而导致 SAM 不再使用
甲基转移酶导致 SAM 积累、增强一碳代谢以及 mTORC1 激活
信号传导,所有这些都支持细胞生长和增殖,与这一假设一致,我们证明了这一点。
限制蛋氨酸的饮食摄入量可减少 KRAS 驱动的肺腺癌生长并逆转
因此,我们将评估针对 SETD2 失活的临床和临床前药物的功效。
蛋氨酸循环与 SETD2 缺陷的潜在合成致命相互作用。
激活 mTORC1 信号传导,我们观察到缺氧诱导因子的显着转录程序
(HIF)和过氧化物酶体增殖物激活受体 γ(PPARγ)共激活剂 1 α(PGC1α)。
观察与 HIF 和 PGC1α 激活增加相关的多种病理生理变化
转录,例如线粒体生物发生的改变和氧化的共同增强
因此,我们将测试这些主转录的要求。
影响 SETD2 失活下游表型的因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Feldser其他文献
David Feldser的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Feldser', 18)}}的其他基金
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma
确定 SETD2 失活对肺腺癌的影响
- 批准号:
10366169 - 财政年份:2021
- 资助金额:
$ 43.91万 - 项目类别:
Deconstructing the multi-faceted roles of Rb in tumor progression
解构 Rb 在肿瘤进展中的多方面作用
- 批准号:
9755390 - 财政年份:2018
- 资助金额:
$ 43.91万 - 项目类别:
Deconstructing the multi-faceted roles of Rb in tumor progression
解构 Rb 在肿瘤进展中的多方面作用
- 批准号:
10227061 - 财政年份:2018
- 资助金额:
$ 43.91万 - 项目类别:
Deconstructing the multi-faceted roles of Rb in tumor progression
解构 Rb 在肿瘤进展中的多方面作用
- 批准号:
10477470 - 财政年份:2018
- 资助金额:
$ 43.91万 - 项目类别:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
确定治疗功效并揭示肿瘤抑制机制
- 批准号:
8616117 - 财政年份:2011
- 资助金额:
$ 43.91万 - 项目类别:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
确定治疗功效并揭示肿瘤抑制机制
- 批准号:
8334638 - 财政年份:2011
- 资助金额:
$ 43.91万 - 项目类别:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
确定治疗功效并揭示肿瘤抑制机制
- 批准号:
8787676 - 财政年份:2011
- 资助金额:
$ 43.91万 - 项目类别:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
确定治疗功效并揭示肿瘤抑制机制
- 批准号:
8240326 - 财政年份:2011
- 资助金额:
$ 43.91万 - 项目类别:
相似国自然基金
基于驾驶人行为理解的人机共驾型智能汽车驾驶权分配机制研究
- 批准号:52302494
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
人机共驾汽车驾驶风险分析及控制权智能交互机理
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
定性与定量分析跟驰行驶中汽车驾驶员情感-行为交互作用机理
- 批准号:71901134
- 批准年份:2019
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
兼顾效率与能效的城市道路智能网联汽车驾驶行为优化及实证研究
- 批准号:71871028
- 批准年份:2018
- 资助金额:46.0 万元
- 项目类别:面上项目
汽车驾驶员疲劳的心理生理检测及神经机制
- 批准号:31771225
- 批准年份:2017
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
In vivo biology of mammalian L1 retrotransposition
哺乳动物 L1 逆转录转座的体内生物学
- 批准号:
10367362 - 财政年份:2022
- 资助金额:
$ 43.91万 - 项目类别:
In vivo biology of mammalian L1 retrotransposition - supplement
哺乳动物 L1 逆转录转座的体内生物学 - 补充
- 批准号:
10578990 - 财政年份:2022
- 资助金额:
$ 43.91万 - 项目类别:
In vivo biology of mammalian L1 retrotransposition
哺乳动物 L1 逆转录转座的体内生物学
- 批准号:
10549834 - 财政年份:2022
- 资助金额:
$ 43.91万 - 项目类别:
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma
确定 SETD2 失活对肺腺癌的影响
- 批准号:
10366169 - 财政年份:2021
- 资助金额:
$ 43.91万 - 项目类别:
TBCK Encephaloneuronopathy: establishing the role of mitochondrial dysfunction in promoting neurodegeneration
TBCK 脑神经病:确定线粒体功能障碍在促进神经退行性变中的作用
- 批准号:
10641750 - 财政年份:2020
- 资助金额:
$ 43.91万 - 项目类别: